We utilized our AI-driven workflow to enhance 3 antibodies with known developability risks. All 3 resulted in variants with substantial improvement. Fewer than 15 variants of each were expressed and tested to achieve the above results.
Case 1: Aggregation reduction of Bevacizumab (Formulated in 50 mM PB buffer, incubated at 52 °C)
Case 2: Improvement of both Tm & Tagg for Eldelumab
Case 3: Viscosity reduction for a highly-viscous antibody